Tango Therapeutics, Inc. Stock-Based Compensation
Tango Therapeutics, Inc. (TNGX) reported Stock-Based Compensation of $27.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Tango Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $16.89M, a 157.11% increase year-over-year.
- Tango Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $10.80M, a 48.82% increase year-over-year.
- Tango Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.98M, a 19.86% decline year-over-year.
- Tango Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $6.63M, a 7.70% decline year-over-year.
- Tango Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $26.43M, a 8.54% decline from fiscal 2024.
- Tango Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $28.90M, a 51.46% increase from fiscal 2023.
- Tango Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $19.08M, a 34.08% increase from fiscal 2022.
- Tango Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $14.23M, a 81.67% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $27.69M 10-Q · filed 2026-08-11 | $33.67M derived: sum of 3 quarters · filed 2026-08-11 | $40.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $10.80M 10-Q · filed 2026-05-13 | $16.78M derived: sum of 2 quarters · filed 2026-05-13 | $23.40M derived: sum of 3 quarters · filed 2026-05-13 | $29.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $12.61M derived: sum of 2 quarters · filed 2026-03-05 | $19.18M derived: sum of 3 quarters · filed 2026-08-11 | $26.43M 10-K · filed 2026-03-05 |
| 2025-09-30 | $6.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $13.20M derived: sum of 2 quarters · filed 2026-08-11 | $20.45M 10-Q · filed 2025-11-04 | $27.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $6.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $13.82M 10-Q · filed 2026-08-11 | $21.29M derived: sum of 3 quarters · filed 2026-08-11 | $28.46M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $7.25M 10-Q · filed 2026-05-13 | $14.72M derived: sum of 2 quarters · filed 2026-05-13 | $21.89M derived: sum of 3 quarters · filed 2026-05-13 | $29.43M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $7.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $14.64M derived: sum of 2 quarters · filed 2026-03-05 | $22.18M derived: sum of 3 quarters · filed 2026-03-05 | $28.90M 10-K · filed 2026-03-05 |
| 2024-09-30 | $7.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $14.72M derived: sum of 2 quarters · filed 2025-11-04 | $21.43M 10-Q · filed 2025-11-04 | $26.31M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $7.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $14.26M 10-Q · filed 2025-08-05 | $19.14M derived: sum of 3 quarters · filed 2026-03-05 | $24.00M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $6.72M 10-Q · filed 2025-05-12 | $11.60M derived: sum of 2 quarters · filed 2026-03-05 | $16.46M derived: sum of 3 quarters · filed 2026-03-05 | $21.58M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $9.74M derived: sum of 2 quarters · filed 2026-03-05 | $14.86M derived: sum of 3 quarters · filed 2026-03-05 | $19.08M 10-K · filed 2026-03-05 |
| 2023-09-30 | $4.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $9.98M derived: sum of 2 quarters · filed 2024-11-06 | $14.20M 10-Q · filed 2024-11-06 | $17.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $5.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $9.34M 10-Q · filed 2024-08-07 | $13.13M derived: sum of 3 quarters · filed 2025-02-27 | $16.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $4.22M 10-Q · filed 2024-05-08 | $8.00M derived: sum of 2 quarters · filed 2025-02-27 | $11.82M derived: sum of 3 quarters · filed 2025-02-27 | $15.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.60M derived: sum of 2 quarters · filed 2025-02-27 | $11.03M derived: sum of 3 quarters · filed 2025-02-27 | $14.23M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $7.24M derived: sum of 2 quarters · filed 2023-11-08 | $10.45M 10-Q · filed 2023-11-08 | $12.70M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $6.63M 10-Q · filed 2023-08-07 | $8.89M derived: sum of 3 quarters · filed 2023-08-07 | $12.32M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $3.21M 10-Q · filed 2023-05-09 | $5.46M derived: sum of 2 quarters · filed 2023-05-09 | $8.89M derived: sum of 3 quarters · filed 2023-05-09 | $10.09M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $5.69M derived: sum of 2 quarters · filed 2023-03-27 | $6.88M derived: sum of 3 quarters · filed 2023-03-27 | $7.83M 10-K · filed 2023-03-27 |
| 2021-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $4.63M derived: sum of 2 quarters · filed 2022-11-10 | $5.58M 10-Q · filed 2022-11-10 | $6.11M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.15M 10-Q · filed 2022-08-10 | $2.68M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $950.00K 10-Q · filed 2022-05-11 | $1.48M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $531.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $1.76M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $1.23M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |